| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NovoCure Limited$16.3
-0.99 (-5.73%)
C 51Pipeline Score MedTech · Commercial
Market Cap
2.08 B
EPS
-1.53
P/E Ratio
-
Value Trade
26.52 M
SEC Financials
Q1 2026Dilution Risk
Revenue
174.06 M
R&D Expenses
58.34 M
Operating CF
-13.52 M
Total Assets
787.93 M
Total Liabilities
457.21 M
Equity
330.72 M
D/E Ratio
12,345
0.79 %
Week
44.14 %
1 Month
58.8 %
3 Month
57.54 %
6 Month
-90.28 %
5 Year
-10.91 %
All Time
Cash Data
Cash Position
97.32 M
Monthly Burn
4.51 M
Runway
19.5 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
1.95 M
52 Week Range
9.82 - 20.06
% held by Insiders
10.11 %
% held by Institutions
86.51 %
Enterprise Value
1.87 B
Total Shares
115.81 M
Short %
11.3 %
Float Shares
105.15 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NovoCure Limited
108Total events
2Upcoming
41Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
Event history 106
Jun 30, 2026
▲EU ApprovalEx-US Regulatory
CE Mark for Optune Pax in locally advanced pancreatic cancer
locally advanced pancreatic cancersource ↗
Jun 18, 2026
◆Topline ReadoutClinical Data
Topline data from Phase 3 TRIDENT trial
newly diagnosed glioblastomasource ↗
Q2 2026
◆Topline ReadoutClinical Data
Topline data from Phase 3 TRIDENT trial in newly diagnosed GBM
newly diagnosed glioblastomasource ↗
Mar 26, 2026
▲Topline ReadoutClinical Data
Positive topline results from Phase 2 PANOVA-4 trial of TTFields therapy for metastatic pancreatic cancer
metastatic pancreatic cancersource ↗
Mar 10, 2026
◆Oral PresentationPresentation
Novocure management to participate in fireside chat at Leerink Global Healthcare Conference
Mar 2, 2026
▲Other Regulator MilestoneEx-US Regulatory
Optune Lua receives reimbursement approval in Japan for NSCLC
non-small cell lung cancersource ↗
Mar 2026
▲FDA ApprovalFDA Decision
Japan MHLW approval of reimbursement for Optune Lua
unresectable advanced/recurrent NSCLCsource ↗
Mar 2026
▲Primary Endpoint MetClinical Data
PANOVA-4 topline results: primary endpoint met (74% DCR vs 48% historical control)
metastatic pancreatic cancersource ↗
Feb 26, 2026
▲FDA ApprovalFDA Decision
U.S. FDA approval of Optune Pax for pancreatic cancer
pancreatic cancersource ↗
Feb 26, 2026
●Quarterly UpdateCorporate
Conference call and webcast to discuss Q4 and full year 2025 financial results
Drug Pipeline Intelligence
C51
Pipeline Score $3.0B
Pipeline ValueValuation Signal
8
Drugs Scored1.5x
rNPV / MCap Top 77%
Small Cap (rank 211 of 911)
Percentile RankNovoCure Limited carries a moderate pipeline score (51/100), with $4.8B risk-adjusted pipeline value, led by Pembrolizumab in Metastatic Non-small Cell Lung Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab Small molecule | Glioblastoma | Phase 3 | NCT03405792 | 46% | $2.8B | ACTIVE NOT_RECRUITING | 781 | - | - | Dec 1, 2027 | MODERATE_RISK | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Optune Pax | locally advanced pancreatic cancer | Phase 3 | 2026-02-12 | statistically significant improvement in overall survival | U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer Read More | |
Optune Pax | locally advanced pancreatic cancer | Phase 3 | 2026-02-12 | statistically significant improvement in overall survival | U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer Read More | |
Optune Pax | locally advanced pancreatic cancer | Phase 3 | 2026-02-12 | statistically significant improvement in overall survival | U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NVCR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NVCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NVCRNovocure to Report Second Quarter 2026 Financial Results
Novocure is set to announce its financial results for the second quarter of 2026. The report will provide insights into the company's performance and financial health during this period. Investors and stakeholders are likely to pay close attention to the results for future projections.
Read more →NVCRNovocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Novocure's Optune Pax® has been granted CE Mark approval for treating locally advanced pancreatic cancer. This marks a significant advancement in therapeutic options for patients suffering from this challenging condition. The approval is expected to enhance treatment strategies and potentially improve patient outcomes.
Read more →NVCR▼ -20%on this news
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Novocure has announced topline data from the Phase 3 TRIDENT trial, which evaluates the earlier use of Tumor Treating Fields therapy in patients with newly diagnosed glioblastoma. The results are expected to provide insights into the therapy's effectiveness in this patient population. Further details on the outcomes and implications of the trial have yet to be disclosed.
Read more →NVCR▲ +27.5%on this news· ran to +39% by day 1
Novocure Reports First Quarter 2026 Financial Results
Novocure reported strong financial results for Q1 2026, with net revenues of $174.1 million, a 12% increase from the previous year. The company achieved key milestones in its commercial and clinical programs, including positive results from the PANOVA-4 trial. However, it also reported a net loss of $71.1 million and a significant rise in general and administrative expenses.
Read more →NVCRNovocure to Report First Quarter 2026 Financial Results
Novocure is scheduled to report its financial results for Q1 2026 on April 30, 2026. A conference call will be held at 8:00 a.m. EDT to discuss these results. The company is known for its innovative cancer treatment, Tumor Treating Fields, and has ongoing clinical trials for various cancers. Novocure emphasizes transparency through its investor relations website.
Read more →NVCRNovocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Novocure has announced positive topline results from its Phase 2 PANOVA-4 clinical trial, which evaluated the efficacy of Tumor Treating Fields (TTFields) therapy for patients with metastatic pancreatic cancer. The results indicate that TTFields may offer a promising treatment option for this challenging condition. Further details on the trial's outcomes and implications are anticipated.
Read more →NVCRNovocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Novocure has received reimbursement approval for its Optune Lua device from Japan's Ministry of Health, Labour and Welfare. This device is intended for adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who have progressed after platinum-based chemotherapy. The approval allows for concurrent use with PD-1/PD-L1 inhibitors, providing a significant treatment option for patients in Japan.
Read more →NVCRNovocure to Participate in 2026 Leerink Global Healthcare Conference
Novocure will participate in the 2026 Leerink Global Healthcare Conference, with CEO Frank Leonard and CFO Christoph Brackmann scheduled for a fireside chat. The event will take place on March 10, 2026, and will include one-on-one meetings with investors. A live audio webcast of the presentation will be available on Novocure's Investor Relations page.
Read more →NVCR▼ -8.3%on this newsshared move
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Novocure reported its financial results for Q4 and full year 2025, highlighting a record number of patients treated with its Tumor Treating Fields therapy. The company announced the FDA approval of Optune Pax for pancreatic cancer, marking a significant milestone. Novocure aims for continued growth with projected revenue contributions from its therapies in 2026.
Read more →NVCR▲ +6.9%on this news· ran to +37% by day 1shared move
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
Novocure announced that British Columbia will cover Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma patients. This coverage follows a recommendation from Canada's Drug Agency, marking a significant milestone in treatment accessibility. The therapy aims to provide patients with a new option that may extend their survival. Novocure is committed to expanding access across Canada.
Read more →NVCR▲ +19.3%on this news
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
The U.S. FDA has approved Novocure's Optune Pax for treating locally advanced pancreatic cancer, marking a significant advancement in nearly three decades. The Phase 3 PANOVA-3 trial demonstrated improved overall survival and pain management without adding systemic side effects. Optune Pax utilizes Tumor Treating Fields to disrupt cancer cell replication, providing a new treatment option for patients.
Read more →NVCRNovocure to Present at 44th Annual J.P. Morgan Healthcare Conference
Novocure announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12-15, 2026. CEO Frank Leonard will present and answer questions on January 14. The company aims to extend survival in aggressive cancer forms through its Tumor Treating Fields therapy. A live audio webcast of the presentation will be available.
Read more →NVCR▼ -8.8%on this news
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
Novocure has appointed Frank Leonard as its new CEO, effective immediately. Leonard, who previously served as President, has been with the company for over 15 years and played a key role in its growth and development. He succeeds Ashley Cordova, who has resigned. Leonard aims to lead Novocure in launching new products and completing clinical trials.
Read more →NVCRNovocure to Participate in 37th Annual Piper Sandler Healthcare Conference
Novocure will participate in the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025. Executive Chairman William Doyle will engage in a fireside chat and hold one-on-one meetings with investors. A live audio webcast of the presentation will be available for 14 days post-event. Novocure focuses on innovative cancer therapies.
Read more →NVCRNovocure Appoints Christoph Brackmann as Chief Financial Officer ROOT, Switzerland - Novocure (NASDAQ NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO).
Novocure has appointed Christoph Brackmann as its next Chief Financial Officer, effective immediately as a Senior Financial Advisor, with a formal transition to CFO set for January 1, 2025. Brackmann previously held the position of Senior Vice President of Finance at Moderna, where he contributed significantly during the COVID-19 pandemic. His experience in financial leadership is expected to aid Novocure in expanding its product offerings and global footprint, particularly in oncology therapeutics.
Read more →NVCR▲ +7.1%on this news
NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
Kahn Swick & Foti, LLC has issued a reminder to investors regarding a class action lawsuit against NovoCure Limited, with a lead plaintiff application deadline of August 18, 2023. The lawsuit claims that NovoCure and its executives did not disclose material information during the class period, violating federal securities laws. Despite reporting positive results from its Phase 3 LUNAR trial for a lung cancer therapy, the stock saw a significant decline in value due to analysts' concerns about the treatment's applicability in standard care protocol. The action is currently pending in the Southern District of New York.
Read more →NVCRNovoCure Limited: Please contact the Portnoy Law Firm to recover your losses; August 18 2023 deadline
NovoCure Limited is facing a lawsuit filed by investors who purchased the Company’s securities during the Class Period of January 5, 2023 to June 5, 2023. The lawsuit alleges that NovoCure made false statements and omitted crucial information regarding the LUNAR study data, which may have significant implications for the Company's regulatory prospects. Interested investors are encouraged to contact the Portnoy Law Firm for potential recovery of losses and to discuss their legal rights.
Read more →NVCRNOVOCURE LIMITED (NASDAQ: NVCR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NovoCure Limited
NovoCure Limited is currently embroiled in a securities class action lawsuit initiated by Bernstein Liebhard LLP on behalf of investors who held shares between January 5, 2023, and June 5, 2023. The lawsuit alleges violations of the Securities Exchange Act of 1934, specifically claiming that the company and its officers made materially false statements regarding the results of the LUNAR study. Following a disclosure on June 5, 2023, that undermined previous positive assertions about the study, NovoCure's stock plummeted by over 43%. Investors interested in acting as lead plaintiffs must file their motions by August 18, 2023.
Read more →NVCR▼ -7.8%on this news
NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
ClaimsFiler has announced that investors in NovoCure Limited have until August 18, 2023, to file lead plaintiff applications in a class action lawsuit against the company. The lawsuit arises from alleged violations of federal securities laws due to the company's failure to disclose important information. Despite reporting positive results from a Phase 3 clinical trial for its Tumor Treating Fields therapy, analysts noted the treatment was not aligned with current standards for lung cancer care. Following the announcement, NovoCure's shares experienced a notable decline.
Read more →NVCRNOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NovoCure Limited
Bernstein Liebhard LLP has issued a class action alert for investors of NovoCure Limited (NVCR) regarding a lawsuit that alleges violations of securities law. The lawsuit claims the company misled shareholders by concealing important details about the LUNAR study results. Following the disclosure of unreliable data, NovoCure's stock plummeted by more than 43%, raising concerns among investors. A deadline for affected investors to file a lead plaintiff motion is set for August 18, 2023.
Read more →NVCRNOVOCURE INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies NovoCure Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP has notified NovoCure investors of a class action lawsuit regarding the company's securities during the specified Class Period. Allegations state NovoCure misrepresented the results of its LUNAR Study, suggesting data reliability issues that were not disclosed. Following the presentation of the full study results, NovoCure's stock fell significantly, highlighting investor concerns about the accuracy of the reported data. A motion to serve as a lead plaintiff can be filed until August 18, 2023.
Read more →NVCRNovoCure Limited (NVCR) Shareholders: Contact Robbins LLP for Information About the Class Action Against NovoCure Limited
NovoCure Limited is facing a class action lawsuit filed by shareholders who allege that the company misled investors regarding the effectiveness of its LUNAR study. The complaint points to concealed data that undermined the positive results touted by NovoCure, including the inadequate evaluation of a patient population receiving standard care therapy. Following the full presentation of the study results, which revealed these significant issues, NovoCure's stock price plummeted by 43%. Shareholders seeking to participate in the class action must file by August 18, 2023.
Read more →NVCRNovoCure Limited (NVCR) Equity Alert: Robbins LLP Urges NVCR Investors with Significant Losses to Contact the Law Firm Regarding the NovoCure Limited Class Action
Robbins LLP has announced a class action lawsuit on behalf of investors in NovoCure Limited (NVCR) who acquired shares between January 5 and June 5, 2023. The lawsuit claims that the company misrepresented the efficacy of its LUNAR study, as it failed to account for a significant number of patients receiving standard care treatment. Following the release of the full study results at an oncology conference, NovoCure's stock experienced a sharp decline of 43%. Affected shareholders are encouraged to participate in the class action proceedings, with a deadline for lead plaintiff applications set for August 18, 2023.
Read more →NVCRNovoCure Limited: Please contact the Portnoy Law Firm to recover your losses; August 18, 2023 deadline
NovoCure Limited is facing legal action from investors who allege that the company made false statements regarding its LUNAR study data. The complaint claims that important information was concealed, casting doubt on the study's reliability and its implications for regulatory approval. Affected investors are encouraged to contact the Portnoy Law Firm for a complimentary legal evaluation. The outcome of this case could have significant effects on NovoCure's regulatory standing and overall operations.
Read more →NVCR▼ -5.8%on this newsshared move
NovoCure Limited (NVCR) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against NovoCure Limited
NovoCure Limited (NVCR) is facing a class action lawsuit filed by shareholders claiming the company misled them regarding the results of its LUNAR study. The complaint asserts that NovoCure failed to disclose crucial details about the study's efficacy, particularly that a small proportion of participants had received standard care therapy. This revelation led to a dramatic drop in the company's stock price, losing 43% of its value within a day. Shareholders have until August 18, 2023, to file to act as lead plaintiff in the class action.
Read more →NVCRNOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against NovoCure Limited
A securities class action lawsuit has been filed against NovoCure Limited, alleging that the company misled investors about the results of its LUNAR study. The complaint claims that NovoCure concealed negative data that negatively impacted the reliability of previously reported results. Following the disclosure of this information, NovoCure's stock price experienced a significant drop of over 43%. The lawsuit emphasizes the firm's responsibility in providing accurate information to investors during the specified class period.
Read more →NVCRNovoCure Limited Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm has launched an investigation on behalf of NovoCure Limited investors who have suffered financial losses. The firm is inviting affected investors to contact them to discuss potential legal rights and options for recovering their losses. The investigation aims to determine whether NovoCure and its officials have committed securities violations or engaged in illegal business activities. The law firm, known for recovering significant funds for investors, is encouraging participation to explore claims against corporate misconduct.
Read more →NVCR▼ -6.1%on this news
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Confirmed objective r
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Confirmed objective response rate was 50% for patients treated with TTFields tog
Read more →NVCRprospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historic
Novocure Announces Expansion of its Executive Leadership Team Wilco Groenhuysen appointed to an expanded Chief Operating Officer role Ashley Cordova promoted to Chief Financial Officer Frank Leonard promoted to Chief Development Officer St. Helier, Jersey - Novocure (NASDAQ N
Read more →NVCRNovocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 20
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to present at the 38th Annual J.P. Morgan Heal
Read more →NVCRNovocure Reports Second Quarter 2019 Financial Results and Provides Company Update Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018 The NovoTTF-100L System FDA approv
Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018 The NovoTTF-100L System FDA approved to treat malignant pleural mesothelioma in combination
Read more →NVCRCMS Establishes 2019 Monthly Fee Schedule Amount for Optune St. Helier, Jersey - Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule
CMS Establishes 2019 Monthly Fee Schedule Amount for Optune St. Helier, Jersey - Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule a
Read more →NVCRMedicare Releases Final Local Coverage Determination Providing Coverage of Optune for Newly Diagnosed Glioblastoma St. Helier, Jersey - Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME)
Medicare Releases Final Local Coverage Determination Providing Coverage of Optune for Newly Diagnosed Glioblastoma St. Helier, Jersey - Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a
Read more →NVCRFDA Approves the NovoTTF-100L System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma trea
FDA Approves the NovoTTF-100L System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In the STELLAR trial, malignan
Read more →NVCRNovocure Reports First Quarter 2019 Financial Results and Provides Company Update Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the four
Novocure Reports First Quarter 2019 Financial Results and Provides Company Update Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018 Mesothelioma humanitarian device exemption
Read more →NVCRNovocure's Chief Science Officer Retires after 17 Years of Service St. Helier, Jersey - Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure's Chief Science Officer and Head of Research an
Novocure's Chief Science Officer Retires after 17 Years of Service St. Helier, Jersey - Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure's Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step
Read more →NVCRNovocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth
Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth versus the third quarter 2018 Full year 2018 net revenues
Read more →NVCRNovocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of mor
Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017 Fourth quarter and full
Read more →NVCRNovocure Reports Third Quarter 2018 Financial Results and Provides Company Update Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the seco
Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) applic
Read more →NVCRNovocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, inclu
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune , in China, Hong Kong, Macau and
Read more →NVCRacordova@novocure.com 212-767-7558
Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control Mesothelioma patients who received Tumor Treating Fields with pemetrexed and
Read more →NVCRNovocure Reports Second Quarter 2018 Financial Results and Provides Company Update Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the f
Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018 Submission of local coverage determinati
Read more →NVCRNovocure Appoints Pritesh Shah as Chief Commercial Officer With extensive experience in oncology, Pritesh Shah will be responsible for Novocure's commercial strategy worldwide St. Helier, Jersey - Novocure (NASDAQ: NVCR)
Novocure Appoints Pritesh Shah as Chief Commercial Officer With extensive experience in oncology, Pritesh Shah will be responsible for Novocure's commercial strategy worldwide St. Helier, Jersey - Novocure (NASDAQ: NVCR) announced today that Pritesh Shah has been appointed as N
Read more →NVCRNovocure Announces Changes to its Board of Directors Former Medivation CEO, Dr. David T. Hung, elected to board of directors Former Avon CEO, Sherilyn D. McCoy, elected to board of directors Gert Lennart Perlhagen retiri
Novocure Announces Changes to its Board of Directors Former Medivation CEO, Dr. David T. Hung, elected to board of directors Former Avon CEO, Sherilyn D. McCoy, elected to board of directors Gert Lennart Perlhagen retiring after 15 years of service St. Helier, Jersey - Novocu
Read more →NVCRNovocure Reports First Quarter 2018 Financial Results and Provides Company Update 2,009 active patients at
Novocure Reports First Quarter 2018 Financial Results and Provides Company Update 2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017 Delivered quarterly net revenues of $52.1 million, representing 49 percent growth versus the first quarter
Read more →NVCRNovocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints Novocure plans to submit a Humanitari
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval S
Read more →NVCRConsolidated Balance Sheets USD in thousands (except share data) December 31, U.S. dollars in thousands, except share and per share data 2017 2016 Liabilities and shareholders' equity Current liabilities: Trade payables
Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update 1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016, and an increase of 9 percent versus September 30, 2017 Delivered record quarterly net
Read more →NVCRNovocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue 1,834 active patients at
Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue 1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016 Fourth quarter 2017 preliminary net revenues of $53.7 million, reflecting 77 percent
Read more →NVCRConsolidated Balance Sheets USD in thousands (except share data) September 30
Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update Third quarter 2017 net revenues of $50.1 million, reflecting 131 percent growth versus third quarter 2016 and 31 percent growth versus second quarter 2017 1,683 active patients at September 30, 20
Read more →NVCRNOVOCURE LIMITED POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION EFFECTIVE AS OF JULY 26, 2017 The Board of Directors (the "Board") of NovoCure Limited (the "Company") shall, to the extent legally permitted, require the r
POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION EFFECTIVE AS OF JULY 26, 2017 The Board of Directors (the "Board") of NovoCure Limited (the "Company") shall, to the extent legally permitted, require the return, repayment or forfeiture of any annual or long-term incentive compen
Read more →NVCRNovocure Reports Second Quarter 2017 Financial Results and Provides Company Update 1,460 active patients at
Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update 1,460 active patients at June 30, 2017, an increase of 64 percent from June 30, 2016, and 15 percent from March 31, 2017 Second quarter 2017 net revenues of $38.4 million, reflecting 114 percent
Read more →NVCRMartin J. Madden Joins Novocure Board of Directors ST. HELIER, Jersey- Novocure today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novoc
Martin J. Madden Joins Novocure Board of Directors ST. HELIER, Jersey- Novocure today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure's 2017 annual general meeting of shareholders. In addit
Read more →NVCRNovocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial
ST. HELIER, N.J., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Novocure (NASDAQ:NVCR) announced today that the first patient has been enrolled in the METIS trial, a phase 3 pivotal trial studying radiosurgery plus Tumor Treating Fields (TTFields) compared to radiosurgery alone for the treat
Read more →NVCRNovocure to Report Third Quarter 2016 Financial Results
ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference c
Read more →NVCRNovoCure Limited (Nasdaq: NVCR) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
ADVISORY, Oct. 02, 2015 (GLOBE NEWSWIRE) -- NovoCure Limited (Nasdaq:NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offering (IP
Read more →Competitive Position
How NVCR ranks across every disease it competes inCompetitive Position is a premium feature
See how NVCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial